Shattuck Labs, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Shattuck Labs, Inc. (STTK) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.73 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- Shattuck Labs, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.73M, a 44.60% increase year-over-year.
- Shattuck Labs, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.42M, a 40.33% increase year-over-year.
- Shattuck Labs, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.78M, a 30.44% decline year-over-year.
- Shattuck Labs, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.89M, a 29.08% decline year-over-year.
- Shattuck Labs, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $7.00M, a 26.72% decline from fiscal 2024.
- Shattuck Labs, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $9.55M, a 37.57% increase from fiscal 2023.
- Shattuck Labs, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $6.94M, a 7.38% increase from fiscal 2022.
- Shattuck Labs, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $6.46M, a 18.20% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.73M 10-Q · filed 2026-08-11 | $5.15M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $2.42M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $7.00M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $1.78M 10-Q · filed 2025-11-06 | $3.67M derived: sum of 2 quarters · filed 2026-08-11 | $5.39M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $1.89M 10-Q · filed 2026-08-11 | $3.61M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $1.72M 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $9.55M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $2.56M 10-Q · filed 2025-11-06 | $5.22M derived: sum of 2 quarters · filed 2025-11-06 | $7.70M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $2.67M 10-Q · filed 2025-11-06 | $5.14M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $2.48M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $6.94M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $1.76M 10-Q · filed 2024-11-14 | $3.62M derived: sum of 2 quarters · filed 2024-11-14 | $5.30M derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $1.85M 10-Q · filed 2024-11-14 | $3.54M derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-03-31 | $1.68M 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $6.46M 10-K · filed 2024-02-29 | |||
| 2022-09-30 | $1.72M 10-Q · filed 2023-11-09 | $3.26M derived: sum of 2 quarters · filed 2023-11-09 | $4.77M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $1.53M 10-Q · filed 2023-11-09 | $3.05M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $1.51M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $5.47M 10-K · filed 2023-02-23 | |||
| 2021-09-30 | $1.34M 10-Q · filed 2022-11-09 | $3.07M derived: sum of 2 quarters · filed 2022-11-09 | $4.25M derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | $1.73M 10-Q · filed 2022-11-09 | $2.91M derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | $1.18M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $1.27M 10-K · filed 2022-03-15 | |||
| 2020-09-30 | $312.00K 10-Q · filed 2021-11-09 | $449.00K derived: sum of 2 quarters · filed 2021-11-09 | $629.00K derived: sum of 3 quarters · filed 2021-11-09 | |
| 2020-06-30 | $137.00K 10-Q · filed 2021-11-09 | $317.00K derived: sum of 2 quarters · filed 2021-11-09 | ||
| 2020-03-31 | $180.00K 10-Q · filed 2021-11-09 | |||
| 2019-12-31 | $461.00K 10-K · filed 2021-03-16 | |||
| 2019-09-30 | $144.00K 10-Q · filed 2020-11-13 | $231.00K derived: sum of 2 quarters · filed 2020-11-13 | $297.00K derived: sum of 3 quarters · filed 2020-11-13 | |
| 2019-06-30 | $87.00K 10-Q · filed 2020-11-13 | $153.00K derived: sum of 2 quarters · filed 2020-11-13 | ||
| 2019-03-31 | $66.00K 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |